COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Zomedica to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Monday, April 1, 2024, at 4:30 p.m. ET
Zomedica Corp. (NYSE American: ZOM) to host conference call on April 1, 2024, discussing operational and financial highlights for Q4 and full year 2023. Company specializes in veterinary health products for companion animals -
COMMUNIQUÉ DE PRESSE
CBMJ's Patriot.TV Demonstrates Visual and Audio Translated Multilingual Content Using Unique Proprietary AI. Alters International Media Landscape Propelling its’ Groundbreaking Media Broadcasting Platform to Global Audiences
Conservative Broadcast Media & Journalism showcases live multilingual translation using AI for TV programs, providing accurate and swift content delivery worldwide -
-
-
-
-
COMMUNIQUÉ DE PRESSE
bSerene Debuts Industry-Leading Calming Product Line for Pets
bSerene introduces a comprehensive lineup of calming solutions for cats and dogs, including targeted products to address specific stressors. The collection features innovative tools like diffusers, sprays, collars, and chews -
COMMUNIQUÉ DE PRESSE
MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
MindBio Therapeutics Corp. commences Phase 2B clinical trial for MB22001 in Major Depressive Disorder patients, following successful Phase 2A trial with significant results -
COMMUNIQUÉ DE PRESSE
MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
Phase 2B trial begins with MB22001 for Major Depressive Disorder patients. Successful Phase 2A trial showed 53% in remission with 14.1 MADRS score drop. MindBio aims to scale up psychedelic treatment for depression
